Figure 7. Hsa-miR-135b-3p binds to the 3′UTR of ALDH2. (A) Gene mutation distribution of UCEC patients detected in TCGA. (B) KM survival curve of the mutant group and non-mutation group. (C) The volcano plot of miRNAs in UCEC patients with TCGA: Red dots and green dots indicate differentially expressed miRNAs based on the fold change P < 0.05. (D) Venn diagram of up-regulated miRNA and predicted binding miRNA. (E) Correlation analysis between the expression of predicted bound miRNA and the expression of ALDH2. (F) Relative Luciferase activity was measured with a dual-luciferase reporter assay. (G) Dual-luciferase assay of the mutation group. (H) RNA pull-down analysis with ALDH2 antibody. (I) RIP assay was further verified for a direct association between hsa-miR-135-3p and ALDH2. (J) Overexpression efficiency of hsa-miR-135-3p mimic. (K) WB analysis the expression of ALDH2 with overexpression of hsa-miR-135-3p. (L) Relative expression of ALDH2 with overexpression of hsa-miR-135-3p by using Image J software. (M) Kaplan-Meier survival curve for patients with UCEC (According to the median value of aldh2 expression, it is divided into two groups of high and low expression). *P < 0.05, **P < 0.01, ***P < 0.001.